Site Sponsor Study Title Breast 40101 CALGB Cyclophosphamide and Doxorubicin (CAx 4 cycles). Paclitaxel ( x4 cycles) as adjuvant therapy for breast cancer in women with 0-3 positive axillary lymph nodes: A phase III randomized trial  24-02 IBCSG A Phase III Trial evaluating the role of Ovarian Function Suppression and the role of Exemestane as Adjuvant Therapies for Premenopausal women with Endocrine responsive breast cancer ** Exemestane and Tamoxifen provided by Pharmacia* E1105 ECOG Randomized Phase III Double-Blind Placebo-Controlled Trial of First Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with Her-2/Neu Over Expressing Metastatic Breast Cancer E5103 ECOG E5103 A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer PACCT-1 ECOG Program for the Assessment of Clinical Cancer Tests: Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial S0226 SWOG Phase III Randomized Trial of an Anastrozole vs. Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer *Fulvestrant provided by Astra-Zeneca for patients for Arm 2* B-42 NSABP A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer AVF4349n Genetech An Observational study of Treatment Patterns and Safety Outcomes for Metastatic or Local Recurrent Breast Cancer GI R-04 NSABP A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum E5204 ECOG Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer E2804 ECOG E2804 -The BeST Trial: A Randomized Phase II study of VEGF, RAF Kinase, mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib, Temsirolimus in Advanced Renal Cell Carcinoma GU E2805 ECOG Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma Heme CML Registry NOVARTIS A Worldwide, Observational Registry collecting Longitudinal Data on the management of Chronic Myelogenous Leukemia (CML) patients (The WORLD CML Registry) in routine practice 1905 ECOG A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplatic type), and Acute Myeloid Leukemia with Multilineage Dysplasia S0106 SWOG Phase III Study of Addition of Mylotarg Induction Therapy vs. Standard Induction with Daunomycin & Ara-C Followed by Consolidation & Subsequent Randomization to Post Consolidation Tx with Mylotarg or No Additional Therapy. *Patients must register for ancillary studies S9007 & S9910 S9007 SWOG Cytogenetic Studies in Leukemia Patients (Ancillary study for SWOG 0106) S9910 SWOG Leukemia Centralized Reference Laboratories and Tissue Repositories (Ancillary study for SWOG 0106) S0777 SWOG Randomized Phase III trial of Lenalidomide and low dose decadron VS bortezomib, Lenalidomide and low dose decadron for induction in patients with previouly untreated Multiple Myeloma without an intent for immediate autologous Stem Cell transplant Lung 1505 ECOG A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) S9925 SWOG Substudy To Establish Central Lung Cancer  Specimen Repository To Serve as a Resource For Current and Future Scientific Studies PrE0501 ALPHA Oncolgy A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination with Docetaxel and Carboplatin ±  Placebo or Maintenance Therapy with Vandetanib in Patients with IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)” Melanoma 1697 ECOG Phase III Randomized Study of Four Weeks High Dose IFN-"2b in Stage T3 - T4 or N1 (microscopic) Melanoma Myeloma E1A05 ECOG Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade)-Lenalidomide (Revlimid)-Dexamethasone (VRD) versus Bortezomib (Velcade)-Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen